Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose

Atherosclerosis

Volumn 225, Issue 2, 2012, Pages 403-407

  Krysiak, Robert ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cytokines; Inflammatory cells; Metformin; Pleiotropic effects; Statins; Systemic inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; FATTY ACID; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; METFORMIN; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CYTOKINES; DRUG SYNERGISM; FASTING; FEMALE; GLUCOSE METABOLISM DISORDERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LIPIDS; LYMPHOCYTES; MALE; METFORMIN; MIDDLE AGED; POLAND; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84869490870     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.09.034     Document Type: Article

References (28)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group. Lancet 1994, 344:1383-1389.
2. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1317.
3. Athyros V.G., Kakafika A.I., Tziomalos K., et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009, 15:479-489.
4. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203:325-330.
5. Krysiak R., Okopien B., Herman Z.S. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003, 63:1821-1854.
6. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. JUPITER Study Group.
7. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696. CARDS investigators.
8. Krysiak R., Gdula-Dymek A., Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011, 107:1010-1018. e1.
9. Pruski M., Krysiak R., Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 2009, 32:1421-1424.
10. Krysiak R., Gdula-Dymek A., Bachowski R., Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care 2010, 33:2266-2270.
11. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
12. Simsek S., Schalkwijk C.G., Wolffenbuttel B.H. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes - the CORALL study. Diabet Med 2012, 29:628-631.
13. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
14. Okopien B., Krysiak R., Kowalski J., et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004, 176:327-335.
15. Krysiak R., Zmuda W., Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012, 271:32-42.
16. Krysiak R., Okopien B. Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients. Pharmacol Rep 2011, 63:95-101.
17. Hansson G.K. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009, 7(1):328-331.
18. Weyand C.M., Younge B.R., Goronzy J.J. T cells in arteritis and atherosclerosis. Cur Opin Lipidol 2008, 19:469-477.
19. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
20. Schroecksnadel K., Frick B., Winkler C., Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006, 4:205-213.
21. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007, 65(12 Pt 2):S253-S259.
22. Trepels T., Zeiher A.M., Fichtlscherer S. The endothelium and inflammation. Endothelium 2006, 13:423-429.
23. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
24. Genuth S. The UKPDS and its global impact. Diabet Med 2008, 25(Suppl. 2):57-62.
25. Krysiak R., Okopien B. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. Metabolism 2012 Jul 26, [Epub ahead of print].
26. Krysiak R, Okopien B. Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose. Basic Clin Pharmacol Toxicol. http://dx.doi.org/10.1111/j.1742-7843.2012.00913.x.
27. Strack T. Metformin: a review. Drugs Today (Barc) 2008, 44:303-314.
28. Petersen J.L., McGuire D.K. Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005, 2:9-15.